Returning for its 2^nd year as the world’s leading industry forum, Dry-AMD Therapeutic Development establishes meaningful clinical endpoints using the latest diagnostic imaging techniques to prove therapeutic safety and efficacy in specific patient populations.

In the context of unprecedented Phase III progress, and as new investigational pharmacological agents enter the clinic, Dry-AMD Therapeutic Development will deliver a greater breadth and depth of technical content than any other meeting in this field with 3 days and 2 tracks of dedicated content.

Uniting large pharma, biotech and academic KOLs with a reimagined agenda, this year’s meeting devotes specific content to the unique discovery, pre-clinical, translational, clinical development and commercialization challenges encountered within the dry-AMD space. Ensuring that whatever your role in the field, you will leave with tangible actions to implement into your strategy and pipeline, to translate the promise of dry AMD therapies into a reality for patients.

Join the 200+ expert community, as they unite under a common goal of accelerating the approval of next generation therapies for this progressive eye disease.

To know more about Dry-AMD Therapeutics Summit please click here.